![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lunglife Ai Inc | LSE:LLAI | London | Ordinary Share | ORD USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -0.69% | 14.40 | 13.80 | 15.00 | 14.50 | 14.40 | 14.50 | 19,886 | 09:42:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLLAI
RNS Number : 1228F
LungLife AI, INC
03 November 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Director share purchases
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company's common shares of US $0.0001 each ("Common Shares") undertaken by directors.
On 2 November 2022, Paul Pagano, Chief Executive Officer, purchased 5,000 Common Shares at a price of 130 pence per share. Following this purchase, Paul Pagano now holds 5,000 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.
In addition, on 2 November 2022, David Anderson, Chief Financial Officer, purchased 5,000 Common Shares at a price of 130 pence per share. Following this purchase, David Anderson now holds 5,000 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO Via Walbrook PR David Anderson, CFO Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970 & Broker) Daniel Adams / Virginia Bull / Cameron MacRitchie Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 / Marriage 07867 984 082
About LungLife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name Paul Pagano --------------------------------- ------------------------------------- 2. Reason for the Notification ------------------------------------------------------------------------ a) Position/status Chief E xecutive Officer --------------------------------- ------------------------------------- b) Initial notification/amendment Initial notification --------------------------------- ------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------ a) Name LungLife AI, Inc --------------------------------- ------------------------------------- b) LEI 549300VBVDIF0Y3OVI38 --------------------------------- ------------------------------------- 4. Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted ------------------------------------------------------------------------ a) Description of the Financial Common shares of $0.0001 each in the instrument, type of instrument, capital of the Company identification code ISIN: USU5500L1045 --------------------------------- ------------------------------------- b) Nature of the Transaction Purchase of Common Shares --------------------------------- ------------------------------------- c) Price(s) and volume(s) Price Volume 130 pence 5,000 ------- --------------------------------- ------------------------------------- d) Aggregated information As above * Aggregated volume * Price --------------------------------- ------------------------------------- e) Date of the transaction 2/11/2022 --------------------------------- ------------------------------------- f) Place of the transaction London Stock Exchange --------------------------------- -------------------------------------
Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name David Anderson --------------------------------- ------------------------------------- 2. Reason for the Notification ------------------------------------------------------------------------ a) Position/status Chief Financial Officer --------------------------------- ------------------------------------- b) Initial notification/amendment Initial notification --------------------------------- ------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------ a) Name LungLife AI, Inc --------------------------------- ------------------------------------- b) LEI 549300VBVDIF0Y3OVI38 --------------------------------- ------------------------------------- 4. Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted ------------------------------------------------------------------------ a) Description of the Financial Common shares of $0.0001 each in the instrument, type of instrument, capital of the Company identification code ISIN: USU5500L1045 --------------------------------- ------------------------------------- b) Nature of the Transaction Purchase of Common Shares --------------------------------- ------------------------------------- c) Price(s) and volume(s) Price Volume 130 pence 5,000 ------- --------------------------------- ------------------------------------- d) Aggregated information As above * Aggregated volume * Price --------------------------------- ------------------------------------- e) Date of the transaction 2/11/2022 --------------------------------- ------------------------------------- f) Place of the transaction London Stock Exchange --------------------------------- -------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBTBFTMTTMBMT
(END) Dow Jones Newswires
November 03, 2022 03:00 ET (07:00 GMT)
1 Year Lunglife Ai Chart |
1 Month Lunglife Ai Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions